357
Productivity & Workflow354
Software Development248
Automation & Workflow238
Marketing & Growth204
AI Infrastructure & MLOps197
Photography & Imaging166
Writing & Content Creation193
Design & Creative170
Data & Analytics165
Customer Support156
Education & Learning144
Voice & Speech130
Sales & Outreach132
Operations & Admin119
Science Corporation raised $400 million in new funding, valuing the brain and vision tech startup at about $3.5 billion, according to TechCrunch.
In short: Science Corporation raised $400 million in new funding, and investors valued the company at about $3.5 billion.
Science Corporation, a medical technology startup founded in 2021 by Max Hodak, said it raised a $400 million Series D round. A Series D is a later funding round, which usually means a company is trying to grow faster.
A person familiar with the deal told TechCrunch the funding puts Science Corporation’s value at $3.5 billion. Investors named in the round include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The company’s first product is called PRIMA. It is a wearable and implantable chip meant to help some people with age-related macular degeneration recover part of their vision. Think of it like adding a small electronic helper to the eye system, so signals can get through in a new way. PRIMA is approved in Europe and available in Germany, and it is also being tested for other vision conditions, including Stargardt’s disease.
With the new funding, Science Corporation says it wants to bring PRIMA to the United States using the FDA’s Humanitarian Device Exemption. This is a special pathway that can allow certain devices for rare conditions to be used sooner, under specific rules.
Science Corporation is also working on a longer-term project that would connect directly to the brain using a sensor made from living neurons (brain cells grown in a lab) and silicon (the material used in computer chips). The company is designing early human trials with Yale neurosurgery professor Murat Günel.
This funding could help get a vision aid to more patients, and it shows investors are willing to put large sums into medical devices that interact with the eye and, eventually, the brain. For patients and families, the key question is whether the trials and regulators show these devices are safe and helpful.
Source: TechCrunch AI